Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Olaparib for BRCA mutated and high risk HER2 negative breast cancer - adjuvant therapy	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Breast cancer	Breast Cancer	2020	View \| Download
Olaparib in addition to abiraterone for metastatic castration-resistant prostate cancer – First line	Abiraterone acetate (Zytiga; Yonsa) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction	Omecamtiv Mecarbil (AMG 423; CK-1827452)	Heart failure (HF)	Cardiovascular System	2020	View \| Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line	Oportuzumab monatox (Vicinium; VB4-845; Proxinium)	Bladder cancer	Urological Cancer	2020	View \| Download
Osimertinib for EGFR-positive non-small cell lung cancer - adjuvant	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
OTL-103 for Wiskott-Aldrich syndrome	OTL-103 (GSK-2696275)	Wiskott-Aldrich syndrome (WAS)	Genetic Disorders , Immunology	2020	View \| Download
Ozanimod for moderate to severe ulcerative colitis	Ozanimod (RPC1063; Zeposia; ozanimod hydrochloride)	Ulcerative colitis	Gastroenterology	2020	View \| Download
Palbociclib for breast cancer - post neoadjuvant therapy	Palbociclib (Ibrance; PD-0332991)	Breast cancer	Breast Cancer	2020	View \| Download
Pegunigalsidase alfa for Fabry disease – first-line	PRX-102 (Pegunigalsidase alfa)	Fabry disease	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2020	View \| Download
Pembrolizumab addition to chemotherapy, followed by maintenance with olaparib for BRCA non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer – First-line	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2020	View \| Download